Compare Enveric Biosciences Inc (ENVB) vs Nextpower Inc. Common Stock (NXT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Nextpower Inc. Common Stock — how do they compare? Enveric Biosciences Inc trades at $1.2 (market cap $6.27M), while Nextpower Inc. Common Stock trades at $81.25 (market cap $13.47B). The key difference: Nextpower Inc. Common Stock is far larger — about 2148.3× Enveric Biosciences Inc's market cap, and Enveric Biosciences Inc is more actively traded (100,675 versus 2,009,302). Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Nextpower Inc. Common Stock for 0 Days on average.
| ENVB | NXT | |
|---|---|---|
Market Cap | $6.27M | $13.47B |
Volume | 100,675 | 2,009,302 |
Sector | Health | Energy |
52-Week High | $10.80 | $156.40 |
52-Week Low | $1.27 | $77.93 |
Typical Hold Time | 14 Days | 0 Days |
Enterprise Value | -$2.03M | $12.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.40, down 4.76% with a bearish technical signal from moving averages. The company shows negative profitability metrics with ROE at -235.48% and no revenue in 2025, though it has consistently beaten EPS estimates. Recent news highlights patent approvals and positive preclinical data for its neuroplastogenic therapeutics.
The outlook remains speculative given the lack of revenue and negative cash flow from operations. Analyst consensus is 75% buy, but high business execution risks and dependence on drug development success pose significant challenges for near-term shareholder value.
NXT trades at $88.77, up 4.61% today, with strong analyst support (86% buy ratings) and a $144.67 consensus price target suggesting 63% upside. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected November 16. Revenue grew from $3.0B in 2025 to $3.6B in 2026, while maintaining robust profitability with 16.36% net margins and 27.22% ROE.
Positive outlook driven by $5.5B+ backlog and raised 2027 guidance, though rising platform investment costs and solar sector volatility present risks. Technical levels show support at $86 with resistance at $91, while valuation multiples (P/E 22.94, P/S 3.76) appear reasonable given growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Nextpower Inc. Common Stock
Nextpower Inc., formerly known as Nextracker, is a solar energy technology company that designs tracking systems, structural foundations, and electrical balance-of-system equipment for utility-scale solar power plants. The company also develops software for solar yield management and is expanding into utility-scale power conversion systems.
Read more on NXT →
